Myriad Genetics (NASDAQ:MYGN) Director S. Louise Phanstiel Buys 50,407 Shares of Stock

Myriad Genetics, Inc. (NASDAQ:MYGN) Director S. Louise Phanstiel purchased 50,407 shares of the business’s stock in a transaction dated Thursday, February 26th. The shares were purchased at an average cost of $4.80 per share, for a total transaction of $241,953.60. Following the purchase, the director directly owned 233,951 shares of the company’s stock, valued at $1,122,964.80. This trade represents a 27.46% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

S. Louise Phanstiel also recently made the following trade(s):

• On Friday, February 27th, S. Louise Phanstiel acquired 48,000 shares of Myriad Genetics stock. The stock was purchased at an average price of $4.66 per share, with a total value of $223,680.00.
• On Wednesday, February 25th, S. Louise Phanstiel acquired 6,100 shares of Myriad Genetics stock. The shares were purchased at an average cost of $4.74 per share, with a total value of $28,914.00.

Myriad Genetics Stock Down 5.1%

Shares of NASDAQ:MYGN opened at $4.61 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.12. The stock has a market cap of $431.08 million, a price-to-earnings ratio of -1.17 and a beta of 1.90. The company has a 50 day moving average of $5.61 and a 200-day moving average of $6.59. Myriad Genetics, Inc. has a one year low of $3.76 and a one year high of $11.44.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Monday, February 23rd. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.06. The firm had revenue of $209.80 million for the quarter, compared to analysts’ expectations of $207.57 million. Myriad Genetics had a negative net margin of 44.38% and a negative return on equity of 6.35%. The business’s revenue for the quarter was down .4% on a year-over-year basis. During the same period last year, the firm earned $0.03 earnings per share. On average, sell-side analysts forecast that Myriad Genetics, Inc. will post -0.3 earnings per share for the current year.

More Myriad Genetics News

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Director S. Louise Phanstiel completed multiple open-market buys totaling ~104,507 shares across Feb. 25–27 (average prices ~$4.74–$4.80), increasing her stake ~20–27% in disclosed filings — a strong insider-confidence signal that can attract investor interest. SEC Form 4 filing
• Positive Sentiment: Zacks Research upgraded MYGN from “strong sell” to “hold,” removing a severe negative rating and potentially reducing selling pressure from some model-driven funds or algorithmic screens. Zacks.com
• Neutral Sentiment: Media coverage amplified the insider activity (TipRanks coverage), which can increase short-term trading volume and retail interest but does not change fundamentals by itself. TipRanks article
• Negative Sentiment: Management updated Q1 FY2026 guidance with revenue of $200.0M–$203.0M (consensus ~$203.5M) and left EPS guidance unspecified — revenue guidance is slightly below consensus and the missing EPS figure creates uncertainty ahead of the quarter, which can pressure the stock if investors focus on short-term top-line weakness. (Company guidance release)

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on MYGN. Wells Fargo & Company cut their price target on shares of Myriad Genetics from $6.50 to $6.00 and set an “equal weight” rating on the stock in a research report on Tuesday. UBS Group cut their target price on shares of Myriad Genetics from $8.00 to $6.00 and set a “neutral” rating on the stock in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Myriad Genetics in a report on Monday, December 29th. TD Cowen restated a “hold” rating on shares of Myriad Genetics in a research report on Tuesday, November 4th. Finally, Piper Sandler reduced their target price on Myriad Genetics from $9.00 to $8.50 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Four research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $9.17.

Institutional Investors Weigh In On Myriad Genetics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Assenagon Asset Management S.A. lifted its holdings in shares of Myriad Genetics by 301.2% in the third quarter. Assenagon Asset Management S.A. now owns 1,304,163 shares of the company’s stock valued at $9,429,000 after purchasing an additional 979,133 shares in the last quarter. Prudential Financial Inc. lifted its stake in Myriad Genetics by 95.1% in the 2nd quarter. Prudential Financial Inc. now owns 342,684 shares of the company’s stock valued at $1,820,000 after acquiring an additional 167,023 shares in the last quarter. Aberdeen Group plc boosted its position in Myriad Genetics by 178.3% during the 3rd quarter. Aberdeen Group plc now owns 639,053 shares of the company’s stock worth $4,620,000 after acquiring an additional 409,460 shares during the last quarter. XTX Topco Ltd grew its stake in shares of Myriad Genetics by 1,240.7% during the 2nd quarter. XTX Topco Ltd now owns 284,357 shares of the company’s stock worth $1,510,000 after acquiring an additional 263,147 shares in the last quarter. Finally, Fisher Asset Management LLC raised its holdings in shares of Myriad Genetics by 20.4% in the second quarter. Fisher Asset Management LLC now owns 1,294,822 shares of the company’s stock valued at $6,876,000 after purchasing an additional 219,607 shares during the last quarter. 99.02% of the stock is currently owned by institutional investors and hedge funds.

Myriad Genetics Company Profile

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.